Evinacumab

Last Updated: 04/28/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 202 publications

Advanced therapy in familial hypercholesterolemia.

Advanced therapy in familial hypercholesterolemia.

Journal: Canadian family physician Medecin de famille canadien

Published: February 12, 2026

Novel Approaches to Lipid Management: Beyond Statins and PCSK9 Inhibitors.

Novel Approaches to Lipid Management: Beyond Statins and PCSK9 Inhibitors.

Journal: Journal of clinical medicine research

Published: January 30, 2026

Update on familial hypercholesterolemia: An expert clinical consensus from the National Lipid Association.

Update on familial hypercholesterolemia: An expert clinical consensus from the National Lipid Association.

Journal: Journal of clinical lipidology

Published: January 07, 2026

Evinacumab with or without lipoprotein apheresis in homozygous familial hypercholesterolaemia.

Evinacumab with or without lipoprotein apheresis in homozygous familial hypercholesterolaemia.

Journal: European journal of preventive cardiology

Published: December 18, 2025

Efficacy of evinacumab by genotype and low-density lipoprotein receptor function in patients with homozygous familial hypercholesterolaemia: A subanalysis from the ELIPSE open-label extension study.

Efficacy of evinacumab by genotype and low-density lipoprotein receptor function in patients with homozygous familial hypercholesterolaemia: A subanalysis from the ELIPSE open-label extension study.

Journal: Atherosclerosis

Published: December 18, 2025

Inhibition of angiopoietin-like protein 3 as a target for managing hypertriglyceridemia.

Inhibition of angiopoietin-like protein 3 as a target for managing hypertriglyceridemia.

Journal: Current opinion in endocrinology, diabetes, and obesity

Published: December 17, 2025

The 2025 ESC/EAS Dyslipidaemia Focused Update: Clinical Interpretation and Practical Implications.

The 2025 ESC/EAS Dyslipidaemia Focused Update: Clinical Interpretation and Practical Implications.

Journal: Cardiovascular drugs and therapy

Published: December 10, 2025

Baseline characteristics and response to evinacumab in females and males with homozygous familial hypercholesterolemia in the ELIPSE OLE study.

Baseline characteristics and response to evinacumab in females and males with homozygous familial hypercholesterolemia in the ELIPSE OLE study.

Journal: American journal of preventive cardiology

Published: December 05, 2025

Authors' Reply to Khan et al. "Evaluating the Effectiveness and Safety of Evinacumab in Treating Hypercholesterolemia and Hypertriglyceridemia: A Systematic Review and Meta-analysis of Randomized Controlled Trials".

Authors' Reply to Khan et al. "Evaluating the Effectiveness and Safety of Evinacumab in Treating Hypercholesterolemia and Hypertriglyceridemia: A Systematic Review and Meta-analysis of Randomized Controlled Trials".

Journal: American journal of cardiovascular drugs : drugs, devices, and other interventions

Published: November 26, 2025

Angiopoietin-like Protein 3 (ANGPTL3) Targeting in the Management of Dyslipidemias.

Angiopoietin-like Protein 3 (ANGPTL3) Targeting in the Management of Dyslipidemias.

Journal: International journal of molecular sciences

Published: November 15, 2025

Lessons from recent clinical trials for the prevention of acute pancreatitis in chylomicronemia syndromes.

Lessons from recent clinical trials for the prevention of acute pancreatitis in chylomicronemia syndromes.

Journal: Current opinion in endocrinology, diabetes, and obesity

Published: November 10, 2025

Future of angiopoietin-like protein 3 inhibitors as a therapeutic agent.

Future of angiopoietin-like protein 3 inhibitors as a therapeutic agent.

Journal: Current opinion in lipidology

Published: November 05, 2025

Showing 1-12 of 202

Last Updated: 04/28/2026